Skip to main content

Table 5 Diabetes medications after GLP-1 RA withdrawal

From: Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study

N

Primary prevention

Secondary prevention

MACE

No MACE

p

MACE

No MACE

P

17

135

14

43

Metformin

10 (58.82%)

124 (91.85%)

0.001

9 (64.29%)

37 (86.05%)

0.115

Pioglitazone

0

30 (22.22%)

0.042

0

4 (9.30%)

0.563

Acarbose

1 (5.88%)

6 (4.44%)

0.551

1 (7.14%)

1 (2.33%)

0.434

Sulfonylureas/meglitinides

8 (47.06%)

78 (57.78%)

0.552

6 (42.86%)

17 (40.48%)

0.875

Insulin

15/17 (88.24%)

81 (60.00%)

0.031

13 (92.86%)

27 (62.79%)

0.044

SGLT-2 inhibitors

3 (17.65%)

67 (49.63%)

0.018

2 (14.29%)

23 (53.49%)

0.013

DPP-4 inhibitors

2 (11.76%)

37 (27.82%)

0.240

5 (35.71%)

17 (39.53%)

0.705